B. Amendments to the specification:

Please amend the specification under the provisions of 37 C.F.R. §1.121 as follows:

After the Abstract of the Disclosure and before the Figures, please add the paper copy of the "Sequence Listing" attached hereto as **Exhibit A**.

Please replace the paragraph on page 4, lines 18-29, with the following amended paragraph:

> **Figure 2 - A**: Shows cleavage of hybrid substrate by reaction of deoxyribozyme 12E (13) (SEQ ID NOs: 1 and 2) modified with biotin; fluorogenic reaction is shown with substrate double end-labeled. Upon cleavage (SEQ ID NOs: 2-4) there is an increase in fluorescence emission of fluorescein **F**, as black hole **BH** quencher is removed. When substrates are attached to surfaces, **F** is substituted with amino group and there is no **BH**. Two other deoxyribozymes **10-23** (14, substrate changes to central 5'rGrU) (SEQ ID NO: 5) and **17E** (15) (SEQ ID NO: 6) may also be used. **B**: Streptavidine complexed with four biotin-labeled deoxyribozymes grabbing and cleaving the fuel in solution. Streptavidine is a tetramer organized in D2 point symmetry, however with an appropriate linker length this should not be a factor.

Please replace the paragraph on page 4, lines 31-33, with the following amended paragraph:

Figure 3: Shows alternative construct having four and six deoxyribozymes attached at double helix (SEQ ID NOs: 7 and 8) or three-way (SEQ ID NOs: 9-11) junction. Wiggly line represents flexible polyethylene glycol spacers.